Artivion announces completion of enrollment in persevere trial

Atlanta , nov. 9, 2023 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the persevere clinical trial. the persevere trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute debakey type i aortic dissection can be treated safely and effectively using the amds hybrid prosthesis.
AORT Ratings Summary
AORT Quant Ranking